Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Bifidobacterium bifidum in Irritable Bowel Syndrome (IBS-Bb-RCT)
jRCTs021210038Completed
- Sponsor
- Biofermin Pharmaceutical
- Start
- Apr 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Placebo with Bifidobacterium bifidum (2 arms). Primary endpoint: Primary: Change in IBS symptom severity at week 12 from baseline. Started Apr 2022; status: completed.
02
Drugs
bifidobacterium bifidum
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on jRCTs021210038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210038.